CN1473567A - 包含阿伐他汀和抗高血压药的联合疗法 - Google Patents

包含阿伐他汀和抗高血压药的联合疗法 Download PDF

Info

Publication number
CN1473567A
CN1473567A CNA031430937A CN03143093A CN1473567A CN 1473567 A CN1473567 A CN 1473567A CN A031430937 A CNA031430937 A CN A031430937A CN 03143093 A CN03143093 A CN 03143093A CN 1473567 A CN1473567 A CN 1473567A
Authority
CN
China
Prior art keywords
compound
prepared according
method disclosed
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA031430937A
Other languages
English (en)
Chinese (zh)
Inventor
Rad
R·A·D·斯科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1473567A publication Critical patent/CN1473567A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
CNA031430937A 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法 Pending CN1473567A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29
US60/057,276 1997-08-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN98808463A Division CN1268053A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法

Publications (1)

Publication Number Publication Date
CN1473567A true CN1473567A (zh) 2004-02-11

Family

ID=22009602

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA031430937A Pending CN1473567A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CN98808463A Pending CN1268053A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CNA031430929A Pending CN1473566A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN98808463A Pending CN1268053A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CNA031430929A Pending CN1473566A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法

Country Status (41)

Country Link
US (2) US20020099046A1 (https=)
EP (1) EP1009400B1 (https=)
JP (2) JP2001514223A (https=)
KR (3) KR20010022477A (https=)
CN (3) CN1473567A (https=)
AP (1) AP1191A (https=)
AR (1) AR016399A1 (https=)
AT (1) ATE285767T1 (https=)
AU (1) AU740424B2 (https=)
BG (1) BG64724B1 (https=)
BR (1) BR9811556A (https=)
CA (1) CA2296723A1 (https=)
CO (1) CO4970724A1 (https=)
DE (1) DE69828413T2 (https=)
DZ (1) DZ2595A1 (https=)
EA (1) EA200000012A1 (https=)
EG (1) EG24678A (https=)
ES (1) ES2234134T3 (https=)
GT (1) GT199800126A (https=)
HR (1) HRP980474A2 (https=)
HU (1) HUP0004318A3 (https=)
ID (1) ID24118A (https=)
IL (2) IL133962A0 (https=)
IS (1) IS5341A (https=)
MA (1) MA26536A1 (https=)
MY (1) MY121008A (https=)
NO (1) NO323987B1 (https=)
NZ (2) NZ502280A (https=)
OA (1) OA11291A (https=)
PA (1) PA8457901A1 (https=)
PE (1) PE107099A1 (https=)
PL (1) PL339091A1 (https=)
PT (1) PT1009400E (https=)
SA (1) SA98190603B1 (https=)
SK (1) SK1432000A3 (https=)
TN (1) TNSN98155A1 (https=)
TR (1) TR200000563T2 (https=)
UY (1) UY25155A1 (https=)
WO (1) WO1999011260A1 (https=)
YU (1) YU2000A (https=)
ZA (1) ZA987839B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656786B2 (en) 1992-05-19 2014-04-23 Novogen Research Pty Ltd Use of isoflavone phyto-oestrogen extracts of soy or clover
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
EP1063991A1 (en) * 1998-03-17 2001-01-03 Warner-Lambert Company Llc Statin-matrix metalloproteinase inhibitor combinations
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
WO2001022976A2 (en) 1999-09-24 2001-04-05 Vasogen Ireland Limited Combination of a statin and ex-vivo treated blood for treating artheroclerosis
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US20030149010A1 (en) * 2001-07-19 2003-08-07 Keller Bradley T. Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
CA2490636A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
CA2547137A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
US20070191438A1 (en) * 2004-04-06 2007-08-16 Rohrer Susan P Methods for the treatment of hypertension
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
ES2342090T3 (es) * 2004-08-25 2010-07-01 Essentialis, Inc. Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos.
BRPI0607142A2 (pt) * 2005-02-17 2009-08-11 Chiesi Farma Spa combinações terapêuticas de manidipina e uma estatina, seu uso e um kit
EP2000137B1 (en) * 2006-03-29 2015-10-21 Kowa Company, Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
MA33056B1 (fr) * 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
JP2016514125A (ja) * 2013-03-12 2016-05-19 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
US10537546B2 (en) 2014-10-23 2020-01-21 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
RU2724338C2 (ru) * 2015-06-30 2020-06-23 Ханми Фарм. Ко., Лтд. Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
AU2017274438A1 (en) * 2016-06-02 2018-12-13 Ana Pharmaceuticals, Inc. Methods and compositions for treatment of hypercalciuria and nephrolithiasis
SI4101454T1 (sl) 2017-01-25 2024-10-30 The George Institute for Global Health Sestavki za uporabo pri zdravljenju hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
IL268997B2 (en) 2017-03-01 2023-09-01 Arena Pharm Inc Preparations containing pgi2 receptor agonists and processes for their preparation
EP3796902A1 (en) 2018-05-16 2021-03-31 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
AU2019309329B2 (en) * 2018-07-26 2025-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法

Also Published As

Publication number Publication date
AP1191A (en) 2003-07-19
KR20030015394A (ko) 2003-02-20
SA98190603B1 (ar) 2006-07-04
NZ530630A (en) 2005-05-27
AR016399A1 (es) 2001-07-04
GT199800126A (es) 2000-01-29
KR20010022477A (ko) 2001-03-15
PA8457901A1 (es) 2000-05-24
AU740424B2 (en) 2001-11-01
CN1473566A (zh) 2004-02-11
JP2005041875A (ja) 2005-02-17
MY121008A (en) 2005-12-30
ZA987839B (en) 2000-02-28
IL133962A0 (en) 2001-04-30
YU2000A (sh) 2002-12-10
SK1432000A3 (en) 2000-12-11
NZ502280A (en) 2002-11-26
CN1268053A (zh) 2000-09-27
DE69828413D1 (de) 2005-02-03
UY25155A1 (es) 2000-12-29
DE69828413T2 (de) 2005-12-08
PE107099A1 (es) 1999-11-06
IS5341A (is) 2000-01-14
CA2296723A1 (en) 1999-03-11
EP1009400A1 (en) 2000-06-21
OA11291A (en) 2003-08-25
DZ2595A1 (fr) 2003-02-22
ID24118A (id) 2000-07-06
AP9801332A0 (en) 1998-09-30
NO323987B1 (no) 2007-07-30
US20020099046A1 (en) 2002-07-25
EP1009400B1 (en) 2004-12-29
PL339091A1 (en) 2000-12-04
AU8458998A (en) 1999-03-22
JP2001514223A (ja) 2001-09-11
MA26536A1 (fr) 2004-12-20
BG64724B1 (bg) 2006-01-31
HUP0004318A2 (hu) 2001-05-28
KR20040106591A (ko) 2004-12-17
TNSN98155A1 (fr) 2005-03-15
EG24678A (en) 2010-04-27
TR200000563T2 (tr) 2000-07-21
BG104075A (en) 2000-09-29
HUP0004318A3 (en) 2002-10-28
PT1009400E (pt) 2005-02-28
CO4970724A1 (es) 2000-11-07
ES2234134T3 (es) 2005-06-16
EA200000012A1 (ru) 2000-08-28
BR9811556A (pt) 2000-08-22
NO20000996D0 (no) 2000-02-28
WO1999011260A1 (en) 1999-03-11
ATE285767T1 (de) 2005-01-15
US20030199492A1 (en) 2003-10-23
NO20000996L (no) 2000-04-27
HRP980474A2 (en) 1999-06-30
IL133962A (en) 2006-07-05

Similar Documents

Publication Publication Date Title
CN1473567A (zh) 包含阿伐他汀和抗高血压药的联合疗法
CN1268052A (zh) 含有氨氯地平和阿多伐他丁的治疗组合物
CN1117566C (zh) 包含氨氯地平和抑制素化合物的联合药物形式
US6262092B1 (en) Mutual salt of amlodipine and atorvastatin
HK1046282A1 (zh) 氨氯地平和阿托伐他汀的共同前体药物
US20040248948A1 (en) Combination therapy
CN1426299A (zh) 抗高血压剂和用途
HK1061807A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
HK1061808A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
HK1029288A (zh) 包含阿伐他汀和抗高血压药的联合疗法
HK1029530B (en) Combination pharmaceutical form comprising amlodipine and a statin compound
HK1029527A (en) Therapeutic combinations comprising amlodipin and atorvastatin
HK1109073A (en) Therapeutic combinations comprising amlodipin and atorvastatin
HK1055249A (en) Antihypertensive agents and use
HK1049162A (en) Mutual salt of amlodipine and atorvastatin
CZ2000319A3 (cs) Kombinační terapie zahrnující amlodipin a statinové sloučeniny
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1061808

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1061808

Country of ref document: HK